Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mel

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Wilderness & Environmental Medicine|September 24, 2025
Special Issue: Space Medicine & Health SystemsEdward J Mel Otten
Wilderness & Environmental Medicine|April 29, 2023
Wilderness Medicine Quo Vadis?Edward J Mel Otten
Dental Clinics of North America|November 20, 2002
Local anesthesia: advances in agents and techniquesJ Mel Hawkins, Paul A Moore
Archives of Disease in Childhood|August 1, 1986
Hereditary multiple glomus tumoursS W Beasley, J Mel, C W Chow, et al.
Animal Reproduction Science|February 3, 2017
Comparison of fertility of liquid or frozen semen when varying the interval from CIDR removal to inseminationBrittany N Richardson, Erin L Larimore, Julie A Walker, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Wilderness & Environmental Medicine|September 24, 2025
Special Issue: Space Medicine & Health SystemsEdward J Mel Otten
Wilderness & Environmental Medicine|April 29, 2023
Wilderness Medicine Quo Vadis?Edward J Mel Otten
Dental Clinics of North America|November 20, 2002
Local anesthesia: advances in agents and techniquesJ Mel Hawkins, Paul A Moore
Archives of Disease in Childhood|August 1, 1986
Hereditary multiple glomus tumoursS W Beasley, J Mel, C W Chow, et al.
Animal Reproduction Science|February 3, 2017
Comparison of fertility of liquid or frozen semen when varying the interval from CIDR removal to inseminationBrittany N Richardson, Erin L Larimore, Julie A Walker, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2015
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyHerbert I Hurwitz, David C Smith, Henry C Pitot, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2015
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation studyJohn F DiPersio, Harry P Erba, Richard A Larson, et al.
Pageof 1